Zipalertinib (CLN-081)

Name: Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Heterogeneity of treatment effect
Published: 2026-09-14T15:39:06-04:00

EGFR exon 20 insertion-mutated non-small-cell lung cancer

Also known as TAS6417

Manufacturer: Taiho Oncology
Regulatory submission: NDA submitted February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Heterogeneity of treatment effect

2 evidence topics · 2 sources

Zipalertinib clinical resistance case report

“After eight months of treatment with CLN081, liquid biopsy revealed the emergence of a secondary EGFR C797S mutation” (opens the source at this quote in a new tab)

Diversity of exon 20 insertion variants

“Sixty-four unique EGFRex20ins were identified” (opens the source at this quote in a new tab)